Revance Therapeutics, Inc.
|
(Name of Issuer)
|
Common Stock, par value $0.001 per share
|
(Title of Class of Securities)
|
761330109
|
(CUSIP Number)
|
+41 22 344 96 36
|
(Name, Address and Telephone Number of Person
|
August 22, 2023
|
(Date of Event Which Requires Filing of this Statement)
|
1
|
NAMES OF REPORTING PERSONS
|
|
|
||
Teoxane SA
|
|
|
|||
|
|
||||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
☐
|
||
(b)
|
☐
|
||||
|
|
||||
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|||
|
|
||||
4
|
SOURCE OF FUNDS (SEE INSTRUCTIONS)
|
|
|
||
OO; WC
|
|
|
|||
|
|
||||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
|
|
☐
|
||
|
|
||||
|
|
||||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
Switzerland
|
|
|
|||
|
|
||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7
|
SOLE VOTING POWER
|
|
|
|
4,445,800
|
|
|
|||
|
|
||||
8
|
SHARED VOTING POWER
|
|
|
||
0
|
|
|
|||
|
|
||||
9
|
SOLE DISPOSITIVE POWER
|
|
|
||
4,445,800
|
|
|
|||
|
|
||||
10
|
SHARED DISPOSITIVE POWER
|
|
|
||
0
|
|
|
|||
|
|
||||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
4,445,800
|
|
|
|||
|
|
||||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
☐
|
||
|
|
||||
|
|
||||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
||
5.0%
|
|
|
|||
|
|
||||
14
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
||
CO
|
|
|
|||
|
|
Item 1.
|
Security and Issuer
|
Item 2. |
Identity and Background
|
Item 3. |
Source and Amount of Funds or Other Consideration
|
Item 4. |
Purpose of Transaction
|
Item 5. |
Interest in Securities of the Issuer
|
Item 6. |
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
|
Item 7. |
Material to Be Filed as Exhibits
|
TEOXANE SA
|
|||
By
|
/s/ Patrice Calvayrac
|
||
Name:
|
Patrice Calvayrac
|
||
Title:
|
Chief Financial Officer
|
Name
|
Present
Business Address |
Present
Principal Occupation |
Citizenship
|
|||
Valérie Taupin
|
Rue de Lyon 105, CH 1203,
Geneva, Switzerland
|
Chief Executive Officer, Teoxane SA
|
France
|
|||
Pierre-Alain Guillaume
|
Avenue du Théâtre 1, P.O. Box
1002, Lausanne, Switzerland
|
Attorney-at-Law, Walder Wyss Ltd.
|
Switzerland
|
|||
Mathieu Howald
|
Route des Jeunes 4, Case postale
252, 1211 Genève 8
|
Switzerland
|
||||
Name
|
Present
Business Address |
Present
Principal Occupation |
Citizenship
|
|||
Valérie Taupin
|
Rue de Lyon 105, CH 1203, Geneva, Switzerland
|
Chief Executive Officer
|
France
|
|||
Patrice Calvayrac
|
Rue de Lyon 105, CH 1203, Geneva, Switzerland
|
Chief Financial Officer
|
Switzerland
|